Prosecution Insights
Last updated: May 29, 2026
Application No. 17/840,633

METAL-PHOSPHORIZED CATALYST FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID AND METHOD FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID USING THE SAME

Final Rejection §102
Filed
Jun 15, 2022
Priority
Nov 02, 2021 — RE 10-2021-0148900
Examiner
COUGHLIN, MATTHEW P
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Korea Institute Of Science And Technology
OA Round
2 (Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
83%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
702 granted / 985 resolved
+11.3% vs TC avg
Moderate +12% lift
Without
With
+11.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
35 currently pending
Career history
1038
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
36.1%
-3.9% vs TC avg
§102
17.9%
-22.1% vs TC avg
§112
14.0%
-26.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 985 resolved cases

Office Action

§102
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 1-16 are pending in the application. Claims 1-4 and 10-12 are rejected. Claims 5, 6, 13 and 14 are objected to. Claims 7-9, 15 and 16 are withdrawn from further consideration. Response to Amendment / Argument Objections and rejections made in the previous Office Action have been overcome by Applicant's amendments to the claims. Therefore, arguments pertaining to these objections and rejections will not be addressed. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-4 and 10-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Du et al. Applied Surface Science 2019, 469, 61-67. Du et al. teach the preparation of Co/Ni materials on nickel foam on page 62 (Section 2.2. Synthesis of CoxNiy-EDTA/NF). The authors subsequently teach the following method on page 62: PNG media_image1.png 228 595 media_image1.png Greyscale The prior art teaches testing of the materials on page 62 including the following: PNG media_image2.png 149 593 media_image2.png Greyscale Accordingly, the prior art teaches using the CoxNiyP-materials as an electrode. As examples, the prior art teaches the following in Figure 4 (page 65): PNG media_image3.png 168 555 media_image3.png Greyscale . Each of the materials above corresponds to a tested electrode containing a material of the instant formula NiCoxPy where x and y are either ~0.5, ~0.25 or ~0.125, each of which is embraced by the instant ranges. Regarding the limitation of a substrate in claims 3 and 10, the prior art teaches nickel foam as further embraced by instant claims 4 and 12. Regarding the limitation of claim 1 that the catalyst compound “catalyzes” a certain reaction or the limitation of claim 3 of “thereby catalyzes” the same reaction, MPEP 2112.01(II) states: "Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). A chemical composition and its properties are inseparable. Therefore, if the prior art teaches the identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Id. […] In this situation, the prior art teaches a material having the formula recited in the instant claims. Furthermore, the instant claims place no limitation on how well or effectively the material need to function as a catalyst. Accordingly, the prior art structure having the identical formula is deemed to anticipate the instant claims. Regarding instant claim 10, the limitation of “An FDCA production reactor,” appears to be an intended use as do the limitations of “for introducing” and “for discharging”. The prior art teaches electrocatalytic testing on page 64. While the reaction of the prior art is not the same, the reaction setup is deemed to anticipate since the manner in which the prior art reactants are introduced to the system can be considered both an inlet and outlet and the entire system can be considered a reactor. The prior art further teaches the use of an electrode system embraced by instant claim 11 for HER measurements in “2.5. Electrochemical measurements” on page 63 including applying a potential. Regarding instant claim 2, the prior art is silent regarding the oxidation state of nickel; however, this appears to a natural consequence of treatment with phosphorus as disclosed in the instant specification on page, lines 18-27. Applicant s directed to MPEP 2112.01: “Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990).” Allowable Subject Matter Claims 5, 6, 13 and 14 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MATTHEW P COUGHLIN whose telephone number is (571)270-1311. The examiner can normally be reached Monday - Friday, 10 am - 6 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MATTHEW P COUGHLIN/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Jun 15, 2022
Application Filed
Nov 14, 2022
Response after Non-Final Action
Sep 04, 2025
Non-Final Rejection mailed — §102
Dec 03, 2025
Response Filed
Apr 01, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12630541
COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1
4y 7m to grant Granted May 19, 2026
Patent 12630500
HEXASUBSTITUTED RADIALENE COMPOUNDS AND APPLICATIONS THEREOF
3y 3m to grant Granted May 19, 2026
Patent 12630538
ANTI-VIRAL COMPOUNDS
2y 10m to grant Granted May 19, 2026
Patent 12630493
ANTI-INFLAMMATORY COMPOUNDS
2y 9m to grant Granted May 19, 2026
Patent 12600706
METHOD FOR MANUFACTURING LOW-VISCOSITY HARDENER
3y 3m to grant Granted Apr 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
83%
With Interview (+11.8%)
2y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 985 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month